HS CONTRARIAN INVESTMENTS, LLCConsent to 2017 Offering • May 22nd, 2017 • Mabvax Therapeutics Holdings, Inc. • Pharmaceutical preparations • New York
Reference is made to the following: (i) that Letter Agreement dated August 16, 2016 (hereinafter referred to as the “August 2016 Letter Agreement”) by and among MabVax Therapeutics Holdings, Inc. (the “Company”) and the undersigned lead investor in the Company’s public offering that closed in August 2016 (the “2016 Public Offering”), (ii) the consent dated March 10, 2017 (the “March 2017 Consent”), and (iii) the second letter agreement dated May 15, 2017 attached hereto as Exhibit A (the “May 2017 Letter Agreement”). Capitalized terms used herein and not defined herein shall have the meanings given to them in the August 2016 Letter Agreement.
